A practical guide to the handling and administration of talimogene laherparepvec in Europe

References

• JohnsonDBPuzanovIKelleyMCTalimogene laherparepvec (T-VEC) for the treatment of advanced melanomaImmunotherapy20157661161926098919
   PubMed Web of Science ®Google Scholar
• SlootSRashidOMZagerJSIntralesional therapy for metastatic melanomaExpert Opin Pharmacother201415182629263925381015
   PubMed Web of Science ®Google Scholar
• TronnierMMitteldorfCTreating advanced melanoma: current insights and opportunitiesCancer Manag Res2014634935625228821
   PubMed Web of Science ®Google Scholar
• AgarwalaSSNeubergDParkYKirkwoodJMMature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I–III melanoma (E1673): a trial of the Eastern Oncology GroupCancer200410081692169815073858
   PubMed Web of Science ®Google Scholar
• ThompsonJFAgarwalaSSSmithersBMPhase 2 study of intralesional PV-10 in refractory metastatic melanomaAnn Surg Oncol20152272135214225348780
   PubMed Web of Science ®Google Scholar
• WeideBEigentlerTKPflugfelderAIntralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responsesCancer Immunol Res20142766867824906352
   PubMed Web of Science ®Google Scholar
• von WussowPBlockBHartmannFDeicherHIntralesional interferon-alpha therapy in advanced malignant melanomaCancer1988616107110743342367
   PubMed Web of Science ®Google Scholar
• SiZHerseyPCoatesASClinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSFMelanoma Res1996632472558819128
   PubMed Web of Science ®Google Scholar
• HeinzerlingLBurgGDummerRIntratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacyHum Gene Ther2005161354815703487
   PubMed Web of Science ®Google Scholar
• MacKieRMStewartBBrownSMIntralesional injection of herpes simplex virus 1716 in metastatic melanomaLancet2001357925552552611229673
   PubMed Web of Science ®Google Scholar
• WatanabeDGoshimaFMoriITamadaYMatsumotoYNishiyamaYOncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10J Dermatol Sci200850318519618226503
   PubMed Web of Science ®Google Scholar
• AndtbackaRHICurtiBDKaufmanHFinal data from CALM: a phase II study of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanomaJ Clin Oncol201533Suppl abstract 9030
   PubMedGoogle Scholar
• UrosevicMFujiiKCalmelsBType I IFN innate immune response to adenovirus-mediated IFN-gamma gene transfer contributes to the regression of cutaneous lymphomasJ Clin Invest2007117102834284617823660
   PubMed Web of Science ®Google Scholar
• HeinzerlingLKunziVOberholzerPAKundigTNaimHDummerROncolytic measles virus in cutaneous T-cell lymphomas mounts anti-tumor immune responses in vivo and targets interferon-resistant tumor cellsBlood200510672287229415961518
   PubMed Web of Science ®Google Scholar
• MelcherAParatoKRooneyCMBellJCThunder and lightning: immunotherapy and oncolytic viruses collideMol Ther20111961008101621505424
   PubMed Web of Science ®Google Scholar
• LichtyBDBreitbachCJStojdlDFBellJCGoing viral with cancer immunotherapyNat Rev Cancer201414855956724990523
   PubMed Web of Science ®Google Scholar
• PolJGRességuierJLichtyBDOncolytic viruses: a step into cancer immunotherapyVirus Adapt Treat20124121
   Google Scholar
• HarringtonKJPuzanovIHechtJRClinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapyExpert Rev Anticancer Ther201515121389140326558498
   PubMed Web of Science ®Google Scholar
• AndtbackaRHKaufmanHLCollichioFTalimogene laherparepvec improves durable response rate in patients with advanced melanomaJ Clin Oncol201533252780278826014293
   PubMed Web of Science ®Google Scholar
• NICE National Institute for Health and Care ExcellenceTalimogene laherparepvec for treating unresectable metastatic melanoma. Technology appraisal [TA410]2016 Available from: https://www.nice.org.uk/guidance/ta410Accessed October 3, 2016
   Google Scholar
• IMLYGIC^® (talimogene laherparepvec) [prescribing information]Thousand Oaks, CAAmgen Inc.2015
   Google Scholar
• IMLYGIC^® (talimogene laherparepvec) [summary of product characteristics]BredaAmgen Europe B.V.2016
   Google Scholar
• LiuBLRobinsonMHanZQICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour propertiesGene Ther200310429230312595888
   PubMed Web of Science ®Google Scholar
• FukuharaHTodoTOncolytic herpes simplex virus type 1 and host immune responsesCurr Cancer Drug Targets20077214915517346106
   PubMed Web of Science ®Google Scholar
• HawkinsLKLemoineNRKirnDOncolytic biotherapy: a novel therapeutic plafformLancet Oncol200231172611905600
   PubMed Web of Science ®Google Scholar
• DranoffGGM-CSF-secreting melanoma vaccinesOncogene200322203188319212789295
   PubMed Web of Science ®Google Scholar
• HarringtonKJHingoraniMTanayMAPhase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neckClin Cancer Res201016154005401520670951
   PubMed Web of Science ®Google Scholar
• HarringtonKJAndtbackaFHICollichioFDisease characteristics, treatment outcomes and safety with talimogene laherparepvec vs GM-CSF in patients with stage IIIB/C and IVM1a melanoma in OPTiMPoster presented at: 11th European Association of Dermato Oncology (EADO) Congress and 8th World Meeting of Interdisciplinary Melanoma/Skin Cancer CentersMarseille, FranceOctober 28–31, 2015
   Google Scholar
• HarringtonKJAndtbackaRHCollichioFEfficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trialOnco Targets Ther201697081709327895500
   PubMed Web of Science ®Google Scholar
• AndtbackaRHRossMPuzanovIPatterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trialAnn Surg Oncol201623134169417727342831
   PubMed Web of Science ®Google Scholar
• PuzanovIMilhemMMMinorDTalimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB–IV melanomaJ Clin Oncol201634222619262627298410
   PubMed Web of Science ®Google Scholar
• ChesneyJCollichioFAndtbackaRHInterim efficacy and safety of a randomized (1:1) open-label phase 2 study of talimogene laherparepvec and ipilimumab vs ipilimumab alone in unresected, stage IIIB–IV melanomaAnn Oncol201627Suppl 637940026681681
   PubMedGoogle Scholar
• LongGVDummerRRibasAEfficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec and pembrolizumab for unresected stage IIIB–IV melanomaPoster presented at: American Society of Clinical Oncology Annual MeetingChicago, IL, USAJune 3–7, 2016
   Google Scholar
• IMLYGIC^® (talimogene laherparepvec) [prescribing information]ZugAmgen Switzerland AG2016
   Google Scholar
• AbdullahHATalimogene laherparepvec: advanced therapy medicinical product (ATMP) – a distinct risk management planPoster presented at: Develop Innovate Advance (DIA) meetingPhiladelphia, PA, USAJune 26–30, 2016
   Google Scholar
• HuJCCoffinRSDavisCJA phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factorClin Cancer Res200612226737674717121894
   PubMed Web of Science ®Google Scholar
• IMLYGIC™ (talimogene laherparepvec) [safety data sheet]Thousand Oaks, CAAmgen Inc.2016
   Google Scholar
• SenzerNNKaufmanHLAmatrudaTPhase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanomaJ Clin Oncol200927345763577119884534
   PubMed Web of Science ®Google Scholar
• AmatrudaTMehnertJWalkerJInterim analysis (IA) of a phase 2 multicenter single arm clinical trial to evaluate biodistribution and shedding of talimogene laherparepvec (T-VEC) in patients (pts) with unresected Stages IIIB–IV melanomaPoster presented at: Society for Melanoma Research (SMR) CongressBoston, MA, USANovember 6–9, 2016
   Google Scholar
• WolchokJDHoosAO’DaySGuidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteriaClin Cancer Res200915237412742019934295
   PubMed Web of Science ®Google Scholar
• SeymourLBogaertsJPerroneARECIST working groupiRECIST: guidelines for response criteria for use in trials testing immunotherapeuticsLancet Oncol2017183e143e15228271869
   PubMed Web of Science ®Google Scholar
• ChoiJHAhnMJRhimHCComparison of WHO and RECIST criteria for response in metastatic colorectal carcinomaCancer Res Treat200537529029319956529
   PubMedGoogle Scholar
• EisenhauerEATherassePBogaertsJNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Eur J Cancer200945222824719097774
   PubMed Web of Science ®Google Scholar
• HarringtonKJAndtbackaRHICollichioFBenefit and risk analysis from the phase III OPTiM trial of talimogene laherparepvec (T-VEC) vs granulocyte-stimulating factor (GM-CSF) in patients with stage IIIB–IV melanomaPoster presented at: 11th European Association of Dermato Oncology (EADO) Congress and 8th World Meeting of Interdisciplinary Melanoma/Skin Cancer CentersMarseille, FranceOctober 28–31, 2015
   Google Scholar
• World Health OrganizationLaboratory Biosafety Manual3rd ed2004 Available from: http://www.who.int/csr/resources/publications/biosafety/en/Biosafety7.pdfAccessed October 3, 2016
   Google Scholar
• RehmanHSilkAWKaneMPKaufmanHLInto the clinic: talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapyJ Immunother Cancer201645327660707
   PubMed Web of Science ®Google Scholar